<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Tang L</submitter><pubmed_abstract>Psoriasis is a chronic and inflammatory skin disorder characterized by inflammation and epidermal hyperplasia. Punicalagin (PUN) is a main active ingredient of pomegranate (&lt;i>Punica granatum&lt;/i> L.) peel with multiple biological activities, such as antibacterial, antioxidant and anti-tumor effects. However, the potential effect of PUN on psoriasis remains unknown. In this study, we want to investigate the pharmacological effect of PUN on psoriasis by using imiquimod (IMQ)-induced psoriatic mice model &lt;i>in vivo&lt;/i> and tumor necrosis factor &lt;i>a&lt;/i> (TNF-α) and interleukin-17A (IL-17A)-stimulated HaCaT cells &lt;i>in vitro&lt;/i>. Our results showed that PUN can effectively alleviate the severity of psoriasis-like symptoms. Mechanistically, PUN potently suppresses the aberrant upregulation of i</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>817526</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8826397</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Punicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion.</pubmed_title><pmcid>PMC8826397</pmcid><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Zheng X</pubmed_authors><pubmed_authors>Yang L</pubmed_authors><pubmed_authors>Li C</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Lu C</pubmed_authors><pubmed_authors>Sun X</pubmed_authors><pubmed_authors>Feng B</pubmed_authors><pubmed_authors>Dai Z</pubmed_authors><pubmed_authors>Li M</pubmed_authors><pubmed_authors>Tang L</pubmed_authors><pubmed_authors>Qiu X</pubmed_authors><pubmed_authors>Li T</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Ye S</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Su Z</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Zheng G</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Punicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion.</name><description>Psoriasis is a chronic and inflammatory skin disorder characterized by inflammation and epidermal hyperplasia. Punicalagin (PUN) is a main active ingredient of pomegranate (&lt;i>Punica granatum&lt;/i> L.) peel with multiple biological activities, such as antibacterial, antioxidant and anti-tumor effects. However, the potential effect of PUN on psoriasis remains unknown. In this study, we want to investigate the pharmacological effect of PUN on psoriasis by using imiquimod (IMQ)-induced psoriatic mice model &lt;i>in vivo&lt;/i> and tumor necrosis factor &lt;i>a&lt;/i> (TNF-α) and interleukin-17A (IL-17A)-stimulated HaCaT cells &lt;i>in vitro&lt;/i>. Our results showed that PUN can effectively alleviate the severity of psoriasis-like symptoms. Mechanistically, PUN potently suppresses the aberrant upregulation of i</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T14:59:22.75Z</modification><creation>2025-04-04T14:59:22.75Z</creation></dates><accession>S-EPMC8826397</accession><cross_references><pubmed>35153790</pubmed><doi>10.3389/fphar.2022.817526</doi></cross_references></HashMap>